We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+33.15%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$400M
AUM Growth
+$119M
Cap. Flow
+$47.5M
Cap. Flow %
11.87%
Top 10 Hldgs %
66.54%
Holding
29
New
10
Increased
11
Reduced
5
Closed
3

Top Buys

Rank Stock Value
1
WX
WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS
WX
+$23.7M
2
OFIX icon
Orthofix Medical
OFIX
+$15.6M
3
ENDP
Endo International plc
ENDP
+$15.3M
4
BIIB icon
Biogen
BIIB
+$13.4M
5
ENTA icon
Enanta Pharmaceuticals
ENTA
+$10.9M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$21.5M
2
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$19.9M
3
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$12.4M
4
NPSP
NPS PHARMACEUTICALS INC
NPSP
+$11.1M
5
VNDA icon
Vanda Pharmaceuticals
VNDA
+$9.85M

Sector Composition

Rank Sector Weight
1 Healthcare 49.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NPSP
1
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$43.1M 10.78%
1,355,152
-484,111
-26% -$11.1M
UTHR icon
2
United Therapeutics
UTHR
$26.3B
$36.9M 9.23%
468,190
+60,024
+15% +$4.39M
FURX
3
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
$33.5M 8.38%
761,764
+111,156
+17% +$4.6M
WX
4
DELISTED
WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS
WX
$27.4M 6.86%
+1,001,514
New +$23.7M
MDCO
5
DELISTED
Medicines Co
MDCO
$24.9M 6.21%
741,355
-93,443
-11% -$2.98M
AFFX
6
DELISTED
Affymetrix Inc
AFFX
$21.3M 5.33%
3,442,140
+5,200
+0.2% +$26.9K
AMAG
7
DELISTED
AMAG Pharmaceuticals
AMAG
$20.3M 5.06%
943,037
+205,851
+28% +$4.86M
TARO
8
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$19.8M 4.94%
260,083
+125,884
+94% +$8.17M
EBS icon
9
Emergent Biosolutions
EBS
$375M
$19.7M 4.92%
1,033,869
+50,200
+5% +$896K
SLXP
10
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$19.2M 4.81%
287,779
-180,164
-39% -$12.4M
CSII
11
DELISTED
Cardiovascular Systems, Inc.
CSII
$17.6M 4.4%
878,254
+255,353
+41% +$5.32M
ENDP
12
DELISTED
Endo International plc
ENDP
$17.3M 4.32%
+380,300
New +$15.3M
BIIB icon
13
Biogen
BIIB
$29.9B
$14.4M 3.61%
+60,000
New +$13.4M
INSY
14
DELISTED
Insys Therapeutics, Inc.
INSY
$14.3M 3.57%
+1,223,595
New +$10M
OFIX icon
15
Orthofix Medical
OFIX
$455M
$13.3M 3.34%
+642,726
New +$15.6M
ENTA icon
16
Enanta Pharmaceuticals
ENTA
$372M
$13.1M 3.26%
+569,493
New +$10.9M
CLVS
17
DELISTED
Clovis Oncology, Inc.
CLVS
$8.6M 2.15%
141,500
+59,000
+72% +$4.18M
ANAC
18
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$7.83M 1.96%
+737,685
New +$6.45M
CHDX
19
DELISTED
CHINDEX INTL INC
CHDX
$6.02M 1.51%
353,429
+18,814
+6% +$326K
ARIA
20
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$5.6M 1.4%
304,460
-1,026,640
-77% -$19.9M
VNDA icon
21
Vanda Pharmaceuticals
VNDA
$312M
$5.56M 1.39%
507,469
-922,329
-65% -$9.85M
SCMP
22
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
$5.34M 1.33%
855,214
+675,226
+375% +$4.22M
LPDX
23
DELISTED
LIPOSCIENCE INC COM
LPDX
$2.23M 0.56%
445,052
+22,789
+5% +$128K
HPTX
24
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
$2.17M 0.54%
+83,142
New +$2.08M
HZNP
25
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$352K 0.09%
+105,000
New +$277K
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q3 2013 Portfolio in Review

As of Q3 2013, Consonance Capital Management held 29 positions worth $400M, up 42% from $281M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Consonance Capital Management deployed $47.5M of net new capital in Q3 2013, opening 10 new positions and adding to 11 existing holdings. Its largest new stake was WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS: 1,001,514 shares worth $27.4M.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, up from 40% a quarter earlier.

On the sell side, the largest reduction was Ariad Pharmaceuticals Inc, an estimated $19.9M trimmed.

  • Consonance Capital Management's largest Q3 2013 buy was WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS: 1,001,514 shares worth $27.4M.
  • Consonance Capital Management added most to Taro Pharmaceutical Industries Ltd. in Q3 2013, an estimated $8.17M increase.
  • Consonance Capital Management's biggest Q3 2013 reduction was Ariad Pharmaceuticals Inc, cutting an estimated $19.9M.
  • Consonance Capital Management fully exited Jazz Pharmaceuticals in Q3 2013, selling an estimated $21.5M.
  • Consonance Capital Management's ten largest holdings make up 67% of its $400M portfolio in Q3 2013.
  • Consonance Capital Management opened 10 new positions and closed 3 in Q3 2013.
  • Consonance Capital Management's portfolio value rose 42% quarter-over-quarter to $400M.

Based on Consonance Capital Management's 13F filing for Q3 2013, filed 14 Nov 2013.